Alector IncChange company Symbol lookupSelect an option...ALEC Alector IncAAPL Apple IncGWRE Guidewire Software IncNXGN NextGen Healthcare IncNB NioCorp Developments LtdO Realty Income CorpBB BlackBerry LtdAL Air Lease CorpVICI VICI Properties IncPWR Quanta Services IncGo
Change company Symbol lookup
Select an option...
ALEC Alector Inc
AAPL Apple Inc
GWRE Guidewire Software Inc
NXGN NextGen Healthcare Inc
NB NioCorp Developments Ltd
O Realty Income Corp
BB BlackBerry Ltd
AL Air Lease Corp
VICI VICI Properties Inc
PWR Quanta Services Inc
Health Care : Biotechnology | Small Cap Value
Company profileAlector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The Company is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. The Company has advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development. Its first product candidate, AL001, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients. Its AL002 targets triggering receptor expressed on myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation.
|
|
|
|
| |
| Latest Earnings Missed Consensus (Q4 ending 12/2022) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q4 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced February 28, 2023 | -$0.63 | Q4 Consensus of 11 analysts | -$0.46 | Difference from consensus | -35.78% | Q1 Earnings will announce | (Unconfirmed) May 3, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
ALEC's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.